539871 Share Price Performance

Community Fair Values

AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
Key Takeaways Rapid network expansion and broader service offerings are increasing test volumes, driving sustained revenue and margin growth through operating leverage and higher-value tests. Focus on quality accreditation, technology, and digital partnerships strengthens market position, improves efficiency, and supports ongoing growth in demand and profitability.
₹1.36k
FV
2.3% undervalued intrinsic discount
19.34%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Updated narrative

View all narratives

Recent 539871 News & Updates

No updates

Thyrocare Technologies Limited Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): 20.05
Gross Margin: 50.74%
Net Profit Margin: 14.69%
Debt/Equity Ratio: 4.5%

View full report ›

Thyrocare Technologies Limited Competitors

View more competitors

About 539871

Founded: 1996
Employees: 1822
CEO: Rahul Guha
WebsiteView website: www.thyrocare.com

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segments include selling of consumables used for collection, and promotion of pathology. Its Imaging Services segments provides selling of radio-pharmaceutical, selling of consumables for reporting. The Others segments include sale of testing equipment and consumables and selling of glucometer and glucostrips under the brand name sugarscan. It has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India. In addition, the company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

Indian Market Performance

7 Days: -1.6%
3 Months: 3.8%
1 Year: -6.5%
Year to Date: -2.0%

Over the last 7 days, the market has dropped 1.6%, driven by a decline of 2.1% in the Financials sector. The market has dropped 6.5% in the last year. Earnings are forecast to grow by 15% annually. Market details ›

💥 How Agentic AI Could Change Every Industry

Richard Bowman

August 2025

This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.

Last Week

Thyrocare Technologies Stock Price